 Connection
Aravindhan Veerapandiyan to Treatment Outcome
This is a "connection" page, showing publications Aravindhan Veerapandiyan has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.331 |
|
|
|
-
Harada Y, Rao VK, Arya K, Kuntz NL, DiDonato CJ, Napchan-Pomerantz G, Agarwal A, Stefans V, Katsuno M, Veerapandiyan A. Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve. 2020 10; 62(4):550-554.
Score: 0.084
-
Veerapandiyan A, Eichinger K, Guntrum D, Kwon J, Baker L, Collins E, Ciafaloni E. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience. Muscle Nerve. 2020 02; 61(2):222-226.
Score: 0.080
-
Veerapandiyan A, Pal R, D'Ambrosio S, Young I, Eichinger K, Collins E, Westesson PL, Kwon J, Ciafaloni E. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy. Neurology. 2018 08 14; 91(7):e620-e624.
Score: 0.072
-
Veerapandiyan A, Chaudhari A, Deo P, Ming X. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS): A pediatric case report with six year follow-up. Mult Scler Relat Disord. 2017 Oct; 17:95-98.
Score: 0.067
-
Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Guridi M, Murphy AP, Reid C, Wandel C, Asher DR, Darton E, Mason S, Potter RA, Singh T, Zhang W, Fontoura P, Elkins JS, Rodino-Klapac LR. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025 Jan; 31(1):332-341.
Score: 0.028
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|